HBI-002
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for HBI-002, covering 2025-05-23 to 2026-01-08. Get the full timeline:
Most recent: Clinical Trial Update: A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD) [Phase 1, Phase 2]